# Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

> **NCT04221217** · PHASE3 · COMPLETED · sponsor: **Mochida Pharmaceutical Company, Ltd.** · enrollment: 120 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** Icosapent

## Key facts

- **NCT ID:** NCT04221217
- **Lead sponsor:** Mochida Pharmaceutical Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-14
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-07-14
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221217, "Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04221217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*